At the same time, some studies have shown that breast cancer patients with ER negative before NAC and high expression of Ki67 are more sensitive to chemotherapy and benefit more after chemotherapy, which may be sensitive factors to predict the efficacy of chemotherapy [20, 21]. This evidence concerns the gene ESR1 and breast carcinoma.